News

Brivaracetam Oral Solution will be manufactured by the company at its manufacturing facility located at Verna, Goa.

Lacosamide Oral Solution USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa

The inspection was conducted from September 15, 2025, to September 19, 2025.

The inspection concluded with zero form 483 observations

Rivaroxaban is used for the treatment of venous thromboembolism

The company remains fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide

Ticagrelor film-coated tablets are indicated to reduce the chances of heart attack, stroke, myocardial infarction (MI) or diseases related to the heart or blood vessels

This product, Allopurinol Tablets USP 200 mg, will be manufactured by Indoco Remedies at their manufacturing facility located at Verna, Goa

The facility received 1 Form 483 at the end of the inspection, which will be responded within timeframe

Earlier, the company had received Official Action Indicated status from USFDA for said facility

Clarity Pharma has over 25 years of experience in bringing products to market and now services over 4,000 Primary Healthcare customers

Varenicline is used to aid smoking cessation treatment

Cetirizine Hydrochloride Tablets USP, 10 mg will be manufactured by the company, at their manufacturing facility located at Goa

Warren Remedies has commenced its commercial production on March 24, 2024 from its Greenfield manufacturing facility located at Aurangabad

The Committee of Executive Directors at its meeting held on March 12, 2024 has approved the same

Warren Remedies has commenced its commercial production on March 1, 2024

The receipt of the Establishment Inspection Report indicates a successful closure of the inspection

Canagliflozin improves glycemic control in adults with type 2 diabetes mellitus

The EU GMP certification will support supplies of drug products to Europe and other territories from this manufacturing site

Total consolidated income of the company increased by 4.29% at Rs 426.91 crore for Q1FY24

The company has received EU GMP certification from the Competent Health Authority of Germany

The EU GMP certification issued by the German Health Authority

The strategic investment by Indoco marks a significant milestone, solidifying its position as a key player in the US market

USFDA had inspected the said facility from February 20, 2023 to February 28, 2023

Total consolidated income of the company increased by 4.70% at Rs 428.66 crore for Q4FY23

The company has received EIR with Voluntary Action Indicated status from USFDA

The inspection was conducted from February 20, 2023 to February 28, 2023

Total consolidated income of the company increased by 11.56% to Rs 399.56 crore for Q3FY23

The inspection was conducted from January 16, 2023 to January 20, 2023

This is the seventh successive USFDA inspection with ZERO 483s for AnaCipher CRO

Post-acquisition Kanakal Wind Energy will be associate of Indoco Remedies

The purpose of entering into the Agreements is to establish the Solar Power Plant at Akkalkot

This inspection was conducted by the Division of New Drug Study Integrity, Office of Study Integrity and Surveillance of USFDA

Cost of acquisition is Rs 1 lakh